STOCK TITAN

Bank of America builds 10.11% stake in Lakefront

Lakefront Biotherapeutics NV (LKFT) reported that Bank of America Corporation has crossed a major shareholding threshold under Belgian transparency rules.

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV (LKFT) reported that Bank of America Corporation has crossed a major shareholding threshold under Belgian transparency rules. On August 18, 2026, Bank of America and its affiliates exceeded the 10% voting rights threshold in Lakefront through a combination of shares and derivative instruments.

As of August 19, 2026, Bank of America and its affiliates held 1,419,144 voting rights and 5,243,453 equivalent financial instruments, representing together 10.11% of Lakefront’s voting rights, based on a denominator of 65,897,071 outstanding shares. The position includes physical-settled rights of use/recall and various cash-settled swap positions across several Bank of America entities.

Positive

  • None.

Negative

  • None.
Total voting rights held (shares + instruments) 6,662,597 voting rights Combined voting rights and equivalent financial instruments held by Bank of America entities after August 18, 2026
Percentage of voting rights held 10.11% Total voting rights in Lakefront Biotherapeutics held by Bank of America entities after the threshold crossing
Direct voting rights (shares) 1,419,144 voting rights Voting rights linked to securities held by Bank of America and affiliates after the transaction
Equivalent financial instruments 5,243,453 voting rights Voting rights that may be acquired via equivalent financial instruments held by Bank of America entities
Denominator (outstanding shares) 65,897,071 shares Currently outstanding Lakefront Biotherapeutics shares used to calculate voting-rights percentages
Threshold crossed 10% Belgian major shareholding threshold for voting rights exceeded by Bank of America
Direct voting rights percentage 2.15% Percentage of Lakefront voting rights held through shares by Bank of America and affiliates after the transaction
Equivalent instruments percentage 7.96% Percentage of Lakefront voting rights represented by equivalent financial instruments held by Bank of America and affiliates
transparency notification regulatory
"Lakefront Biotherapeutics NV ... received a transparency notification from Bank of America"
A transparency notification is a public alert required by market rules when a shareholder’s stake in a listed company rises above or falls below specified levels of ownership. It tells investors who is gaining or losing influence — like seeing someone start to buy or sell large slices of a cake — and matters because such moves can signal changes in control, voting power, potential alliances or takeover interest, which can affect share value and investor decisions.
equivalent financial instruments financial
"owned 1,419,144 voting rights and 5,243,453 equivalent financial instruments"
Financial assets or contracts that provide the same or very similar economic exposure, risks, and returns as one another, such as two ways to gain the same market exposure through different products. For investors this matters because choosing between equivalents is often about cost, convenience, tax treatment or counterparty risk—like picking between two routes that get you to the same destination but differ in tolls, travel time and safety. Recognizing equivalents helps compare options and manage portfolio risk efficiently.
voting rights financial
"crossed above the threshold of 10% of Lakefront’ voting rights"
Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.
denominator financial
"Denominator 65,897,071"
The denominator is the number on the bottom of a fraction that shows the total population or base used to calculate a rate, percentage or ratio — for example, the total shares outstanding when calculating earnings per share, or all trial participants when reporting a safety rate. It matters to investors because changing the denominator (by issuing more shares, changing the population measured, or narrowing the base) can make percentages and per‑unit figures look better or worse even if the underlying raw numbers stay the same, much like changing the size of a pizza makes each slice appear larger or smaller.
Right to Recall financial
"Merrill Lynch International | Right to Recall"
Swaps financial
"Bank of America, National Association | Swaps | 15/10/2027"
A swap is a private contract in which two parties agree to exchange streams of future payments or obligations—commonly swapping a fixed payment for a variable one, or exchanging cash flows tied to different interest rates or currencies. Investors use swaps to change their exposure to interest rates, currency moves or credit risk without buying or selling the underlying asset, which can lower financing costs, hedge against unwanted swings, or be used to speculate on market changes.

FAQ

What did Lakefront Biotherapeutics (LKFT) announce regarding Bank of America’s shareholding?

Lakefront Biotherapeutics announced that Bank of America Corporation, as controlling entity, crossed above the 10% voting rights threshold in Lakefront on August 18, 2026, triggering a Belgian transparency notification received on August 19, 2026.

How large is Bank of America’s total position in LKFT after the August 2026 transactions?

Bank of America and its affiliates held 1,419,144 voting rights and 5,243,453 equivalent financial instruments, for a combined total of 6,662,597 voting rights, representing 10.11% of Lakefront Biotherapeutics’ voting rights.

What is the share count used as denominator for Lakefront Biotherapeutics (LKFT) in this notification?

The transparency notification uses a denominator of 65,897,071 currently outstanding Lakefront Biotherapeutics shares to calculate the percentages of voting rights and equivalent financial instruments.

How are Bank of America’s LKFT holdings split between shares and derivative instruments?

After the transaction, Bank of America and affiliates held 2.15% of Lakefront’s voting rights through shares and 7.96% through equivalent financial instruments (including rights of use/recall and swaps), totaling 10.11% of voting rights.

Which Bank of America entities hold Lakefront Biotherapeutics (LKFT) voting rights directly?

Entities listed with voting rights include BofA Securities, Inc., Bank of America, National Association, Merrill Lynch International, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and U.S. Trust Company of Delaware, together holding 1,419,144 voting rights.

What types of equivalent financial instruments on LKFT does Bank of America report?

Reported equivalent financial instruments include Right to Recall, Rights of Use, and multiple swaps, some physically settled and others cash-settled, giving exposure to 5,243,453 voting rights, or 7.96% of Lakefront’s voting rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).


On August 24, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

(c) Exhibit 99.1. Press release dated August 24, 2026


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: August 25, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from Bank of America Corporation on August 19, 2026. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 10% of Lakefront’ voting rights on August 18, 2026, following the acquisition of Lakefront voting rights and equivalent financial instruments.

On August 19, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 1,419,144 voting rights and 5,243,453 equivalent financial instruments, representing together 10.11% of Lakefront’ currently outstanding 65,897,071 shares.

Summary of the transactions:

Date on which the threshold was crossed Date of notification Direct voting rights after the transaction Equivalent financial instruments after the transaction Total (%)
voting rights
August 18, 2026 August 19, 2026 2.15% 7.96% 10.11%

Content of the notification from Bank of America Corporation:
The notification dated August 19, 2026, contains the following information:
·        Date of notification: August 19, 2026
·        Date on which the threshold is crossed: August 18, 2026
·        Threshold of voting rights crossed (in %): 10%
·        Notification by: Bank of America Corporation
·        Denominator: 65,897,071
·        Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
·        Notified details:

A) Voting Rights Previous notification After the transaction
  # of voting rights # of voting rights % of voting rights
Holder of voting rights   Linked to securities Not linked to securities Linked to securities Not linked to securities
Bank of America Corporation 0 0   0.00%  
Bank of America, National Association 14,348 10,701   0.02%  
Merrill Lynch International 8,234 0   0.00%  
BofA Securities, Inc. 600,314 1,407,905   2.14%  
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
462 462   0.00%  
U.S. Trust Company of Delaware 76 76   0.00%  
Subtotal 623,434 1,419,144   2.15%  
  TOTAL 1,419,144 0 2.15% 0.00%


B) Equivalent financial instruments After the transaction
Holder of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
Merrill Lynch International Right to Recall     262,775 0.40% physical
Merrill Lynch International Rights of Use     34,089 0.05% physical
BofA Securities, Inc. Right to Use     4,757,362 7.22% physical
Bank of America, National Association Swaps 15/10/2027   434 0.00% cash
Bank of America, National Association Swaps 15/06/2027   13,414 0.02% cash
Bank of America, National Association Swaps 30/06/2028   27 0.00% cash
Bank of America, National Association Swaps 31/07/2028   3,061 0.00% cash
Merrill Lynch International Swaps 15/01/2027   13,448 0.02% cash
Merrill Lynch International Swaps 30/04/2027   134,182 0.20% cash
Merrill Lynch International Swaps 30/06/2027   213 0.00% cash
Merrill Lynch International Swaps 15/06/2027   13,414 0.02% cash
Merrill Lynch International Swaps 09/09/2027   2,933 0.00% cash
Merrill Lynch International Swaps 29/01/2027   3,741 0.01% cash
Merrill Lynch International Swaps 31/03/2027   222 0.00% cash
Merrill Lynch International Swaps 30/09/2027   44 0.00% cash
Merrill Lynch International Swaps 26/02/2027   4,050 0.01% cash
BofA Securities, Inc. Swaps 30/09/2027   44 0.00% cash
  TOTAL     5,243,453 7.96%  


TOTAL (A&B) # of voting rights % of voting rights
  6,662,597 10.11%

The chain of control has been described at the end of the notification (section 11) and can be found here.

About Lakefront® Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.


1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

Filing Exhibits & Attachments

1 document